Carotid and valvular calcifications in end stage renal disease

Abstract EN

Background : in dialysis patients, both atherosclerosis and arteriosclerosis are highly prominent.

Feting A is a glycoprotein produced predominantly by the liver in adults.

Feting A is known as the most powerful systemic inhibitor of vascular calcification.

Aim of work: To study both carotid and volvuli calcification in end-stage renal disease (ESRD) and some of biomarkers including feting-A, high sensitivity C-reactive protein (hs-CRP), and interleukin 6 (IL-6).

Subjects and methods : Fifty three patients with (ESRD) aged (31.2 ± 8.1 years); 32 patients were men and 21 women, on regular hemodialysis (HD).

They were divided into two groups ; 27 of them of less than five years duration on hem dialysis ; and 26 of more than five years duration.

Compared with seventeen ; apparently healthy persons.

All studied persons were assessed by: CBC; lipid profile, serum albumin; calcium; phosphate; calculated calcium phosphate product (caxp); Feting-A, hs-CRP, and IL-6, performed by using ELISA kits.

Doppler for carotid arteries, and echocardiography to the heart.

Results: There were sixteen (30.2 %) patients with calcified valves; and 23 (43.4 %) calcified carotid arteries.

Feting-A was significantly reduced (p = 0.002), and no significant difference was detected in both hs-CRP (p = 0.400) ; and IL-6 (p = 0.464) between ESRD patients and controls.

Conclusion : patients with ESRD on chronic HD treatment are predisposed to morbidity from cardiovascular disease more than healthy persons.

Controlling the process of vascular calcification (VC) can help patients with ESRD in limiting these cardiovascular problems.

Low feting-A is independent risk factor for VC which acts as inhibitory factor for this process.

Keywords: ESRD.

Feting A, Vascular calcification.